Liu Yongchang, Liu Shichang, Xu Jia, Xu Xiaocheng, Wang Meiyun
Department of Vascular Surgery, Affiliated Hangzhou First People's Hospital, ZheJiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Department of Pharmacy, Weifang Mental Health Center, Weifang, Shandong Province, People's Republic of China.
J Inflamm Res. 2023 Feb 18;16:701-705. doi: 10.2147/JIR.S397470. eCollection 2023.
Kimura's disease (KD) is a rare, chronic inflammatory disease. Clinically, subcutaneous nodules of the head and neck are typical manifestations, often accompanied by local lymphadenopathy or salivary gland enlargement, but there is also systemic damage, such as kidney involvement. Due to the lack of specific markers and imaging examination is not specific, it is difficult to clinically diagnose accurately and can be easy to misdiagnose. The treatment of KD is still not standardized and overtreatment can affect the quality of life.
The case of a 26-year-old man complaining of chest pain with self-conscious progressive lymphadenopathy after receiving Pfizer BioNTech COVID-19 vaccine for more than 1 month is presented. Eosinophil levels were normal and IgE elevated and the final diagnosis of KD was eventually confirmed by lymph node biopsy, which revealed lymphadenopathy with extensive eosinophilic infiltration in the right neck. Treatment was prednisone combined with methotrexate, resulting in satisfactory control.
This case demonstrates that that Kimura disease can involve systemic lymphadenopathy, not only in the head and face or regional lymphadenopathy, suggested that KD should be excluded in patients with systemic lymphadenopathy. The current patient's response to treatment suggested that corticosteroid combined with disease-modifying antirheumatic drugs (DENARDs) was a promising treatment for KD patients with systemic damage. It is worth noting that the mechanism of immunity in the pathogenesis of KD still needs to be further studied.
木村病(KD)是一种罕见的慢性炎症性疾病。临床上,头颈部皮下结节是典型表现,常伴有局部淋巴结肿大或唾液腺肿大,但也存在全身损害,如肾脏受累。由于缺乏特异性标志物且影像学检查不具特异性,临床上难以准确诊断且易误诊。KD的治疗仍不规范,过度治疗会影响生活质量。
本文介绍了一名26岁男性的病例,该患者在接种辉瑞BioNTech新冠疫苗1个多月后出现胸痛并自觉进行性淋巴结肿大。嗜酸性粒细胞水平正常,IgE升高,最终经淋巴结活检确诊为KD,活检显示右颈部淋巴结肿大伴广泛嗜酸性粒细胞浸润。治疗采用泼尼松联合甲氨蝶呤,病情得到满意控制。
该病例表明木村病可累及全身淋巴结肿大,而非仅局限于头面部或区域性淋巴结肿大,提示对于全身淋巴结肿大的患者应排除KD。目前该患者的治疗反应表明,糖皮质激素联合改善病情抗风湿药(DMARDs)对有全身损害的KD患者是一种有前景的治疗方法。值得注意的是,KD发病机制中的免疫机制仍需进一步研究。